4-Methylmorpholine → tert-Butyl (R)-4-((R)-3-(6-cyano-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate

HRID 1096629노트

반응식

HRID 1096629 반응식
[CH3:1][O:2][CH2:3][CH2:4][CH2:5][N:6]1[C:10]2[CH:11]=[C:12]([C:15]#[N:16])[CH:13]=[CH:14][C:9]=2[N:8]=[C:7]1[C@@H:17]1[CH2:22][CH2:21][CH2:20][NH:19][CH2:18]1.[C:23]([O:27][C:28]([NH:30][C@H:31]([CH2:36][C:37]1[CH:46]=[CH:45][C:44]2[C:39](=[CH:40][CH:41]=[CH:42][CH:43]=2)[CH:38]=1)[CH2:32][C:33](O)=[O:34])=[O:29])([CH3:26])([CH3:25])[CH3:24].CN1CCOCC1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F>CN(C=O)C.O>[C:15]([C:12]1[CH:13]=[CH:14][C:9]2[N:8]=[C:7]([C@@H:17]3[CH2:22][CH2:21][CH2:20][N:19]([C:33](=[O:34])[CH2:32][C@H:31]([NH:30][C:28](=[O:29])[O:27][C:23]([CH3:24])([CH3:25])[CH3:26])[CH2:36][C:37]4[CH:46]=[CH:45][C:44]5[C:39](=[CH:40][CH:41]=[CH:42][CH:43]=5)[CH:38]=4)[CH2:18]3)[N:6]([CH2:5][CH2:4][CH2:3][O:2][CH3:1])[C:10]=2[CH:11]=1)#[N:16]

참가 물질

7

반응물 4

HCID 79724-MethylmorpholineHCID 7021578(R)-3-((tert-butoxycarbonyl)amino)-4-(naphthalen-2-yl)butanoic acidHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 66784785(R)-1-(3-Methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole-6-carbonitrile

생성물 1

HCID 66791751tert-Butyl (R)-4-((R)-3-(6-cyano-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate수율 80%

시약·촉매·용매 2

HCID 962Water용매HCID 6228Dimethylformamide용매

실험 절차

(R)-1-(3-Methoxypropyl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole-6-carbonitrile (41E) (0.20 mmol, 80 mg) in DMF (6 mL) was added (R)-3-(tert-butoxycarbonylamino)-4-(naphthalen-2-yl)butanoic acid (0.22 mmol, 72 mg) and N-methylmorpholine (0.80 mmol, 0.09 mL). The reaction mixture was stirred at it for 5 min and then added HATU (0.22 mmol, 84 mg) and kept stirring at it overnight. The reaction mixture was poured into H2O, extracted with EtOAc. The extract was washed with H2O, NaHCO3, brine, dried over MgSO4 and filtered. The filtrate was concentrated in vacuo and purified by preparative LC/MS (40-90% CH3CN in H2O) to afford tert-Butyl (R)-4-((R)-3-(6-cyano-1-(3-methoxypropyl)-1H-benzo[d]imidazol-2-yl)piperidin-1-yl)-1-(naphthalen-2-yl)-4-oxobutan-2-ylcarbamate (41F) (0.16 mmol, 100 mg, yield: 80%). ESI-MS: m/z 610.5 (M+H)+.

후처리

  1. extractionextracted with EtOAc
  2. washThe extract was washed with H2O, NaHCO3, brine
  3. dry with materialdried over MgSO4
  4. filtrationfiltered
  5. concentrationThe filtrate was concentrated in vacuo
  6. custompurified by preparative LC/MS (40-90% CH3CN in H2O)

출처 및 근거

ORD 기록
ord-28ba5e71cdb44c328f8c25e6047102ca
출처 데이터셋
uspto-grants-2012_03
특허 번호
US08138168B1

반응 노트

불러오는 중…